P. Albertsen

发表

Prostate specific antigen best practice statement: 2009 update.

Peter H Gann, Peter C Albertsen, Misop Han, 2009, The Journal of urology.

The role of increasing detection in the rising incidence of prostate cancer.

B A Miller, P C Albertsen, B. Kramer, 1995, JAMA.

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.

J. Stanford, L. Clegg, F. Gilliland, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.

S. Goldenberg, M. Roach, B. Davis, 2013, The Journal of urology.

J. Ware, S. D. Keller, N. Aaronson, 1997, Urology.

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.

R A Stephenson, P C Albertsen, J. Stanford, 2000, JAMA.

Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study.

J. Stanford, F. Gilliland, J. Eley, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.

F. Hamdy, D. Neal, J. Donovan, 2008, The Lancet. Oncology.

Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells.

V. Laudone, S. Kurtzman, L. Miller, 1997, The Journal of urology.

Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells.

V. Laudone, S. Kurtzman, L. Miller, 1998, Urology.

The impact of co-morbidity on life expectancy among men with localized prostate cancer.

D. Fryback, B. Storer, P. Albertsen, 1996, The Journal of urology.

Long-term survival among men with conservatively treated localized prostate cancer.

D. Fryback, B. Storer, P. Albertsen, 1995, JAMA.

Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.

J. Stanford, F. Gilliland, J. Eley, 2001, Journal of the National Cancer Institute.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

C. Roehrborn, G. Andriole, P. Walsh, 1998, The New England journal of medicine.

Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study

L. Holmberg, F. Hamdy, D. Neal, 2015 .

Active surveillance for prostate cancer: a systematic review of the literature.

M. Cooperberg, P. Carroll, C. Parker, 2012, European urology.

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

T. Peters, P. Fayers, D. Aston, 2019, European urology.

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, The Journal of urology.

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

J. Hanley, M. Barry, D. Gleason, 1999, JAMA.

Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

J. Stanford, F. Gilliland, J. Liff, 1999, Journal of the National Cancer Institute.

Long-term functional outcomes after treatment for localized prostate cancer.

J. Stanford, D. Penson, T. Koyama, 2013, The New England journal of medicine.

Early-stage prostate cancer. When is observation appropriate?

P. Albertsen, Peter C. Albertsen, P. Albertsen, 1996, Hematology/oncology clinics of North America.

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

R A Stephenson, P C Albertsen, J. Stanford, 2000, Journal of the National Cancer Institute.

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study.

M. Barry, J. Wennberg, A. Potosky, 1996, Journal of the National Cancer Institute.

A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.

M. Barry, B. Littenberg, T. Bubolz, 1993, JAMA.

Expression of vascular endothelial growth factor receptors in human prostate cancer.

P C Albertsen, V. Laudone, L. Miller, 1999, Urology.

The impact of PSA testing frequency on prostate cancer incidence and treatment in older men

W. Shih, P. Albertsen, G. Lu-Yao, 2011, Prostate Cancer and Prostatic Diseases.

Assessment of the feasibility and impact of shared decision making in prostate cancer.

J H Wasson, P C Albertsen, V. Laudone, 1998, Urology.

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.

F. Hamdy, D. Neal, J. Donovan, 2008, The Lancet. Oncology.

Screening for prostate cancer is neither appropriate nor cost-effective.

P. Albertsen, P. Albertsen, 1996, The Urologic clinics of North America.

Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients

J. Catto, P. Albertsen, F. Thomas, 2013, British Journal of Cancer.

A 72-year-old man with localized prostate cancer.

P. Albertsen, P. Albertsen, 1995 .

Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study

L. Holmberg, F. Hamdy, J. Donovan, 2015 .

Does a positive margin always mandate adjuvant radiotherapy?

Peter C Albertsen, Peter C. Albertsen, P. Albertsen, 2015, BJU international.

Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.

H. Welch, D. Gorski, P. Albertsen, 2015, The New England journal of medicine.

Indonesian prostate cancer risk calculator (IPCRC): an application for predicting prostate cancer risk (a multicenter study).

G. Andriole, A. Vickers, M. Roobol, 2015, Acta medica Indonesiana.